SG Americas Securities LLC Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)

SG Americas Securities LLC acquired a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 14,062 shares of the company’s stock, valued at approximately $179,000. SG Americas Securities LLC owned approximately 0.06% of UroGen Pharma at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in URGN. ProShare Advisors LLC purchased a new position in UroGen Pharma in the 2nd quarter valued at approximately $199,000. Main Street Financial Solutions LLC acquired a new stake in UroGen Pharma in the 2nd quarter valued at about $403,000. Tidal Investments LLC purchased a new position in UroGen Pharma during the 1st quarter valued at about $425,000. Coastal Bridge Advisors LLC raised its position in UroGen Pharma by 4.1% during the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock worth $646,000 after acquiring an additional 1,500 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in UroGen Pharma by 73.1% during the first quarter. BNP Paribas Financial Markets now owns 39,795 shares of the company’s stock worth $597,000 after acquiring an additional 16,799 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on URGN. Guggenheim initiated coverage on UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Trading Down 2.7 %

NASDAQ URGN opened at $12.13 on Thursday. The company has a market cap of $284.45 million, a P/E ratio of -3.70 and a beta of 1.11. UroGen Pharma Ltd. has a 12 month low of $10.60 and a 12 month high of $20.70. The company has a debt-to-equity ratio of 3.23, a current ratio of 8.15 and a quick ratio of 7.93. The company has a 50-day moving average of $13.30 and a 200-day moving average of $14.32.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to the consensus estimate of $23.69 million. As a group, equities analysts predict that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.